대한뉴팜

Daehan New Pharm’s health functional food brand, 'DiNU', has officially launched its online store. The newly opened DiNU online store offers new products like ‘DiNU Paraotics’ and ‘DiNU Polis,’ along with renewed versions of ‘Ascorbic Acid’ and ‘MSM,’ which have been professionally distributed by Daehan New Pharm, now directly available to consumers. To celebrate the official store opening, DiNU is running events with various benefits and plans to continuously provide reliable health information. The online store supports convenient access to health information and product purchases not only on PC but also in mobile environments. Additionally, subscription services allow consumers to receive health supplements that require long-term consistent intake via automatic payment and delivery without needing to buy every time. Daehan New Pharm plans to continue developing and launching high-quality, high-functionality products under the slogan, "Redefining nutrition and focusing on function." As part of the opening celebration, members who purchase ‘DiNU Polis’ throughout February will receive an additional same product for free. There is also an ongoing event where participants writing reviews have a chance to win Starbucks coupons. New members are offered various other benefits as well.

The health functional food brand 'DiNU: define nutrition' has launched ‘Paraotics.’ Paraotics is the first product in Korea to apply a dual-capsule formulation using the ‘capsule-in-capsule’ technology. The capsule containing probiotics is coated with an enteric coating and then enclosed within another capsule containing natural prebiotic ingredients. Unlike conventional probiotic products that have only a single coating, this dual-capsule design enhances the delivery and survival rate of probiotics in the intestines. The inner capsule contains four patented strains of probiotics from Danisco (La-14, Lpc-37, Lp-115, BI-04) and Lactobacillus rhamnosus GG, known for its high intestinal adherence, along with prebiotics, probiotic cultures (postbiotics), and probiotic cell lysates (parabiotics). All probiotic strains included have been clinically proven for efficacy, and the formulation includes an effective number of viable bacteria. The outer capsule contains New Zealand golden kiwi powder, which is distinct from traditional purified prebiotics, as it is made by pulverizing whole natural kiwis, allowing intake of dietary fiber and valuable vitamins and minerals. Clinical studies have confirmed that consuming freeze-dried kiwi powder promotes the growth of beneficial gut bacteria. The dual-capsule technology used in DiNU Paraotics is designed to dissolve sequentially in the stomach and intestines, maximizing the effectiveness of probiotics by delivering active ingredients to the appropriate site. This formulation technology is a first in health supplements, and the goal is to apply dual-release technology to functional ingredients in the future to enhance their absorption and efficacy. Taking two capsules daily provides 5 billion probiotics. The specially designed container allows easy storage at room temperature. DiNU Paraotics, along with DiNU Polis and other DiNU health supplements, are available for purchase on the Naver Smart Store 'DiNU store'. According to the Korea Health Supplements Association report on the functional food market and consumer survey, the health supplement market size reached approximately 4.98 trillion KRW last year, growing 6.6% from 2019. The probiotic market, in particular, expanded sharply by 19% to 885.6 billion KRW from 741.5 billion KRW the previous year. Industry experts expect the probiotic (functional probiotics) market to surpass 1 trillion KRW this year.

The company announced on the 11th that it achieved an accumulated operating profit of 22.1 billion won in the third quarter of 2021, marking a 12% increase year-on-year. Revenue grew 10% to 125.6 billion won, while net profit surged 123% to 14 billion won. All financial indicators showed improvement, with the current ratio—a measure of financial stability—rising by 42.8 percentage points to 179%, and the debt ratio decreasing by 36 percentage points to 96%. The pharmaceutical division contributed to sales growth through the launch of the new dyslipidemia combination drug “Newtozet” and the domestically exclusive carbohydrate absorption inhibitor “Migbos Film-Coated Tablet.” The company is also preparing to expand its diabetes medication portfolio next year by launching a generic version of a DPP-4 inhibitor, aiming to further boost revenue with new product introductions. In the health supplement division, the company is expanding its “DiNU (Define Nutrition)” brand, launched in the second half of this year. Starting with a dual-functional propolis combining Brazilian green propolis and vitamin C, it has released 3g of ascorbic acid from DSM (UK) and OptiMSM from the U.S. On the 11th, it will introduce “Pharaotics,” a probiotic product utilizing Korea’s first “cap-in-cap” technology. In the animal health division, the company plans to obtain product approval for “Trax Injection,” an antibacterial treatment for livestock respiratory diseases, with a commercial launch scheduled for this year. Since the patent expiration in the second half of 2019, domestic manufacturers have been able to produce and sell tulathromycin-based products. The tulathromycin market has grown from around 3 billion won before the patent expiry to approximately 9 billion won, and this product is expected to contribute to sales growth. The company continues to invest steadily in research and development across human pharmaceuticals, veterinary medicines, biopharmaceuticals, and health supplements, with new product launches progressing as planned. By achieving its fourth-quarter goals, the company aims to successfully close 2021 and move forward toward meeting its three-year targets through active recruitment in management, sales, R&D, and manufacturing.

The company launched its health supplement brand DiNU (Define Nutrition) on August 17. Under the slogan “The most ideal health supplement focused on functionality,” the DiNU product line is now available for purchase on Naver Smart Store. Based on the company’s pharmaceutical identity, the DiNU brand emphasizes product functionality. It began with the release of DiNU Propolis, a chewable tablet focused on oral antibacterial benefits, and plans to sequentially launch additional products this year—including probiotics that survive through the intestines and high-absorption collagen products. In addition, the company will directly supply 100% ascorbic acid and 100% MSM products, which are currently sold in hospitals, through its online store. In line with its commitment to sustainability, DiNU has adopted Earth Pack, a 100% biodegradable packaging material, and uses eco-friendly materials for packaging and shipping. The company also minimizes printed materials such as manuals and brochures, opting instead for digital content to further expand its environmental consideration. Going forward, DiNU aims to redefine the concept of nutrition through formulation and ingredient development focused on functionality. The brand plans to deliver various functional health supplements directly to consumers and engage them through diverse promotional events that make the brand approachable and familiar.

The company announced that its accumulated operating profit for the first half of 2021 reached 13.9 billion won, marking a 13% increase year-on-year. Revenue rose 13% to 83.8 billion won, while net profit grew 19% to 8.9 billion won. Strong performance continued in the second quarter, with revenue of 44.2 billion won, up 14% from the same period last year. Operating profit increased 8% to 7.2 billion won, and quarterly net profit climbed 22% to 4.7 billion won. The company attributed its strong results to a focused sales strategy centered on key product lines. Robust sales were reported for Liporase Injection (a wellness injection), Thymosin Injection and Vita d Injection (immune boosters), as well as new and exclusive products including the dyslipidemia combination drug “Newtozet,” the fat absorption inhibitor “Zero be,” and the carbohydrate absorption inhibitor “Migbos Film-Coated Tablet,” which is exclusively marketed in Korea. In the second half of the year, the company plans to launch its new health supplement brand “DiNU (Define Nutrition)”, built on its pharmaceutical expertise and carrying the slogan “The most ideal health supplement focused on functionality.” New products will roll out sequentially from late August. Sales of injection products and newly launched items continue to grow steadily, and the company plans to promote “DiNU” aggressively to ensure a successful market entry and further drive revenue growth. Additionally, the relocation of the Central Research Center and Bio Research Center to the Pangyo Industry-Academia Cooperation Center has strengthened the company’s R&D pipeline, underscoring its evolution into a research-driven pharmaceutical enterprise.

The company continued its growth momentum in 2021. In the first quarter of 2021, it achieved an operating profit of 6.6 billion won, representing a 17% increase year-on-year. Revenue rose 11% to 39.4 billion won, while net profit also increased 10% to 4 billion won. The company attributed its overall performance improvement to the success of its strategic focus on core product lines and systematic distribution network management, both of which have been in place since the previous year. Steady results continue through the company’s management efficiency strategy, which includes proactive risk management measures. Sales of Zero be Capsule, a fat absorption inhibitor launched in 2020, and Avatri Tablet, a triple combination drug for hypertension and hyperlipidemia, have been steadily growing. In 2021, the company further accelerated growth with the domestically exclusive launch of “Migbos Film-Coated Tablet.” Increased sales of core products and improvements in the distribution structure continue to drive sustainable performance growth. With the completion of the company’s Industry-Academia Research Center in Pangyo Second Techno Valley, its R&D capabilities have been further strengthened, enabling the development of a broader range of products to sustain long-term growth.

Daehan New Pharm has completed the construction of its Industry-Academia Research Center in Pangyo Second Techno Valley. The newly built Daehan New Pharm Industry-Academia Research Center, located near the Daewangpangyo Interchange, spans from five basement levels to nine floors above ground and has been designed to become a new landmark in the area. The center was established with the themes of “research and development” and “communication” to enhance work efficiency and employee welfare. The basement and the first and second floors house lobbies, a main auditorium, and seminar rooms, providing spaces for collaboration. To maximize synergy among its pharmaceutical, veterinary, and bio divisions, the company relocated its Central Research Center from Hyangnam and its Bio Research Center from Osong to Pangyo. The new facility also lays the groundwork for open innovation. Daehan New Pharm will form a consortium with Semyung University’s and University of Suwon’s affiliated research institutes, which will jointly occupy the center. The company plans to continuously promote industry-academia collaboration through these partnerships. The establishment of the Daehan New Pharm Industry-Academia Research Center marks a significant milestone in the company’s growth as a pharmaceutical and biotechnology enterprise. Internally, it will serve as a workplace that fosters employee pride and engagement.

Daehan New Pharm Co., Ltd. has launched two new livestock feed supplements, “Choyu 99” and “Custan,” designed to help prevent livestock diseases. Choyu 99 is a high-purity colostrum-based probiotic complex that promotes intestinal health in calves. The company signed a supply agreement with a leading U.S. colostrum distributor known for its premium-grade colostrum, which contains high levels of IgA (Immunoglobulin A) and IgG (Immunoglobulin G). With a purity of 99.8%, Choyu 99 provides the immune benefits of colostrum in a fast and convenient way. Colostrum feeding is recognized as the most essential factor in preventing diseases in newborn calves. Immune substances that prevent diarrhea can only be delivered through colostrum, which must be administered within 24 hours after birth. Although calves need colostrum equivalent to more than 6% of their body weight, most mother cows do not produce sufficient quantities. Therefore, feeding frozen colostrum or colostrum-based supplements has become indispensable. Custan is a natural complex formulation combining highly bioavailable curcumin with special-coated tannic acid, designed to enhance immunity and support antiviral, antibacterial, anti-inflammatory, and productivity-improving effects. Trials in growing and finishing pigs—particularly those difficult to treat during antibiotic withdrawal periods—showed that Custan significantly improved diarrhea symptoms. Moreover, when administered before and after vaccination, including foot-and-mouth disease shots, it significantly reduced abscess formation. Numerous studies and case reports have confirmed that enhanced immunity and disease resistance contribute greatly to improving productivity across various swine production stages. As a combination of these two active ingredients, Custan can deliver maximum effects even with short-term administration (5–7 days), depending on the farm’s conditions. The company stated its commitment to continued collaboration and joint development with technological partners, aiming to contribute to the livestock and related industries as a sustainable and socially responsible enterprise that pursues shared growth.

Daehan New Pharm has launched “Avatri Tablet,” the first triple combination drug in Korea containing atorvastatin, amlodipine, and valsartan. Avatri Tablet is designed to offer enhanced medication convenience for patients with hypertension and dyslipidemia. According to data from the Health Insurance Review and Assessment Service (HIRA), about 31.9% of hypertensive patients receive concurrent treatment for dyslipidemia, and the number of such comorbid cases is rapidly increasing. Combination therapies such as Avatri are known to improve long-term treatment adherence in hypertension and dyslipidemia management. Compared with patients taking separate medications, those on fixed-dose combination therapies had a 117% lower risk of discontinuation, with an average treatment duration of 35 months versus 7 months for separate dosing. Additionally, the UMPIRE study confirmed that fixed-dose combination therapy improves medication adherence by 33%. The efficacy of Avatri Tablet in controlling seated systolic blood pressure (siSBP) and low-density lipoprotein cholesterol (LDL-C) was verified through clinical trials. After eight weeks of administration, the Avatri group showed a 22.75 mmHg reduction in siSBP, compared to a 5.4 mmHg reduction in the valsartan/atorvastatin comparator group. In lipid control, Avatri also demonstrated remarkable results. After eight weeks, the Avatri -treated group showed a 47.15% reduction in LDL-C, whereas the control group receiving amlodipine/valsartan showed an increase in LDL-C levels. By combining three active ingredients to treat two diseases, Avatri provides effective regulation of lipid and blood pressure levels, making it highly beneficial for preventing cardiovascular diseases in hypertensive patients with dyslipidemia who require intensive treatment and management. The company stated that Avatri has strong potential for development in various forms, including those aimed at improving medication adherence, and reaffirmed its commitment to developing improved new drugs with superior therapeutic efficacy.